Adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tub-040-for-patients-with-platinum-resistant-ovarian-cancer-or-relapsed-refractory-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:00:47 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tub-040-for-patients-with-platinum-resistant-ovarian-cancer-or-relapsed-refractory-non-small-cell-lung-cancer/ This clinical trial is focused on studying two types of cancer: platinum-resistant high-grade ovarian cancer and relapsed/refractory adenocarcinoma non-small cell lung cancer. The treatment being tested is a new medication called TUB-040, which is delivered through an intravenous infusion. The purpose of the study is to investigate the safety and tolerability of this new treatment in patients whose cancer has not responded to standard therapies.

The study will be conducted in two phases. In the first phase, different doses of TUB-040 will be tested to determine the safest and most effective dose. This phase will help identify any side effects and how the body processes the medication. In the second phase, the focus will be on optimizing the dose and further assessing the safety and preliminary effectiveness of TUB-040 in treating the cancers.

Participants in the study will receive the medication through an intravenous infusion, and their health will be closely monitored throughout the trial. The study aims to gather important information that could lead to new treatment options for patients with these challenging types of cancer. Some participants may receive a placebo as part of the study design. The trial is expected to continue until early 2027, with recruitment starting in mid-2024.

]]>